Skip to content
MARKETS / NASDAQ / LNSR
NASDAQ · SURGICAL & MEDICAL INSTRUMENTS & APPARATUS · SMALL CAP

Lensar, Inc. LNSR

7 fiscal years on record · USD · FY2025 reported · SEC filings only
$51.7M
▲ 12.4% YoY
$-34.3M
$-14.9M
In brief

What this company does

As of December 31, 2025, LENSAR had approximately 150 employees that support its manufacturing, research and development, commercial and administrative functions. Primarily all of the company's workforce is based at its corporate headquarters in Orlando, Florida. LENSAR was incorporated in the State of Delaware on August 20, 2004 and became a direct, majority-owned subsidiary of PDL BioPharma, Inc. in 2017. As of December 31, 2025, the company owned approximately 292 issued patents and 105 pending patent applications globally.

Written from the business description in LENSAR, Inc.'s annual report to the U.S. Securities and Exchange Commission, filed 31 March 2026. Every sentence was checked against that document before publication.

Growth
USD 51.7M
Revenue, FY2025 · full 7-year series below
Revenue $M Net income $M
FY2025 · Revenue 51.7 · Net income -34.3
20M40M-20M2019202020212022202320242025
Compound annual growth
+20.6%
+17.8%
3 yrs
5 yrs
10 yrs
15 yrs

Revenue compounded at +17.8% a year over five years.

Compound annual rates per period — left blank where that exact year isn't on file, the series crosses a loss, or (per-share rows) a split falls inside the window.

Profitability
−66 cents
lost on every revenue dollar
Operating margin Net margin
FY2025 · Operating -47.6% · Net -66.4%
-50%2019202020212022202320242025
ROE
FY2024 · ROE -164.0%
-50%-100%-150%2019202020212022202320242025

Cash & shareholders
returned in FY2025 · dividends + net buybacks
Free cash flow $M
FY2025 · FCF -14.9
-5M-10M2019202020212022202320242025

Total assetsUSD 71.4M
EquityUSD -26.0M
CashUSD 13.0M
Current ratio1.15×

Equity funds -36% of total assets.

The 7-year record
7 fiscal years
Every figure from documents filed with the SEC · USD

EPS, diluted, dividend per share and shares outstanding are shown without shading, and a vertical line marks the year the share count changed — the series crosses a large, unexplained change in share count, so the years on either side are not on a comparable scale.

row low → row highnegative
Metric 2025202420232022202120202019
Revenue $B0.10.00.00.00.00.00.0
Operating income $B−0.0−0.0−0.0−0.0−0.0−0.0−0.0
EBITDA $B−0.0−0.0−0.0−0.0−0.0−0.0−0.0
Income tax $B·······
Net income $B−0.0−0.0−0.0−0.0−0.0−0.0−0.0
Free cash flow $B−0.0−0.0−0.0−0.0−0.0−0.0−0.0
EPS, diluted $−2.87−2.73−1.31−1.96−2.09−4.28−13.70
Dividend / sh $·······
Payout %·······
ROE %·−164.0−38.1−41.1−32.1−107.9·
Shares out B0.010.010.010.010.010.010.00

Slide the table for earlier years · "·" marks a figure not available in our data for that year.

Provenance
Company facts, as filed
How we verify · 0 failures in 28 reconciliationsAUDITED

Reconciled in 7 of 19 fiscal years. 60 checks could not be computed.

EPS recomputationBalance-sheet identityGross profitBalance-sheet liquiditymoeda_consistente0 failures
ActivitySurgical & Medical Instruments & Apparatus
Listed onNASDAQ
Incorporated inDelaware
Fiscal year endsDecember 31
SEC categorysmaller reporting company
Data on record since2019

Share this section

Download image